Cytori to Begin Stem Cell Trial for Heart Disease

05-Jan-2007

Cytori Therapeutics received approvals to initiate a clinical trial in Spain to investigate the use of adipose-derived stem and regenerative cells for the treatment of cardiovascular disease. The cells will be obtained at the bedside from the patients' own adipose (fat) tissue and made available in real-time using Cytori's Celution' stem and regenerative cell processing system. Patient enrollment will begin imminently.

Cytori's trial, designated as the 'PRECISE' study, will primarily evaluate safety and feasibility in 36 patients with chronic ischemia, a severe form of coronary artery disease. The Company's Celution' stem and regenerative cell processing system will extract and concentrate a patient's cells in the catheterization suite so they are available for the physician to re-inject into damaged heart muscle in about an hour. A variety of clinical functional and imaging endpoints will be assessed in the study. The outcomes of the study will be evaluated after a six month follow up.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances